Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.20 is 489% above its 3-year average of 0.03, near the high end of its 3-year range (-0.09–0.20).
As of the fiscal period ended Tuesday, June 30, 2026. 77.31% above its 12-month average of 0.11.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.20.
DEBT TO EQUITY RATIO
0.20
DEBT TO EQUITY RATIO AVG TTM
0.11
DEBT TO EQUITY RATIO AVG 3Y
0.06
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+77.31%
CURRENT VS 3Y AVG
+207.53%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 766 covered companies
CURRENT VS SECTOR MEDIAN
+81.20%
vs the sector median at left
Kyverna Therapeutics, Inc.
Market Cap
$376.93M
Debt to Equity Ratio
0.20
TTM Avg
0.11
3Y Avg
0.06
5Y Avg
N/A
Market Cap
$376.65M
Debt to Equity Ratio
0.13
TTM Avg
0.12
3Y Avg
0.17
5Y Avg
0.17
Market Cap
$374.16M
Debt to Equity Ratio
0.40
TTM Avg
0.56
3Y Avg
1.08
5Y Avg
0.88
Market Cap
$384.61M
Debt to Equity Ratio
0.00
TTM Avg
1.03
3Y Avg
0.52
5Y Avg
0.41
Market Cap
$384.81M
Debt to Equity Ratio
0.55
TTM Avg
0.43
3Y Avg
0.28
5Y Avg
0.21
Market Cap
$362.65M
Debt to Equity Ratio
N/A
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$358.65M
Debt to Equity Ratio
8.91
TTM Avg
0.02
3Y Avg
0.15
5Y Avg
0.15
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | $376.93M | 0.20 | 0.11 | 0.06 | N/A |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $376.65M | 0.13 | 0.12 | 0.17 | 0.17 |
| Canopy Growth Corporation (CGC)vs › | $374.16M | 0.40 | 0.56 | 1.08 | 0.88 |
| YD Bio Limited Ordinary Shares (YDES)vs › | $384.61M | 0.00 | 1.03 | 0.52 | 0.41 |
| Orthofix Medical Inc. (OFIX)vs › | $384.81M | 0.55 | 0.43 | 0.28 | 0.21 |
| Opus Genetics, Inc. (IRD)vs › | $362.65M | N/A | 0.00 | 0.00 | 0.00 |
| REGENXBIO Inc. (RGNX)vs › | $390.42M | 0.96 | 1.43 | 0.83 | 0.60 |
| Embecta Corp. (EMBC)vs › | $358.64M | N/A | 0.01 | 0.00 | 0.00 |
| Turn Therapeutics Inc. (TTRX)vs › | $358.65M | 8.91 | 0.02 | 0.15 | 0.15 |
| Viemed Healthcare, Inc. (VMD)vs › | $356.51M | 0.08 | 0.08 | 0.07 | 0.08 |
Debt/Equity
0.20
Current Ratio
9.06
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.20 |
| 2026-03-31 | 0.17 |
| 2025-12-31 | 0.12 |
| 2025-09-30 | 0.03 |
| 2025-06-30 | 0.03 |
| 2025-03-31 | 0.03 |
| 2024-12-31 | 0.03 |
| 2024-09-30 | 0.03 |
| 2024-06-30 | 0.03 |
| 2024-03-31 | 0.03 |
| 2023-12-31 | 0.18 |
| 2023-09-30 | -0.09 |
| 2023-06-30 | 0.03 |
| 2023-03-31 | 0.00 |
| 2022-12-31 | 0.00 |
